Jefferies analyst Anthony Petrone believes the FDA's approval of the license transfers of BIVIGAM and Nabi-HB to ADMA Biologics represents an "unofficial" end to regulatory headwinds inherited as part of the Biotest transaction. Although an official FDA close-out letter is yet to be issued, the totality of positive ruling is a strong indication that items in the November 2014 warning letter have been effectively addressed, Petrone tells investors in a research note. The analyst says shares of ADMA are "too cheap" given the progress it has made. He keeps a Buy rating on the name with an $8 price target.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here